Alumis Inc. (ALMS)
NASDAQ · Manufacturing · Pharmaceutical preparations
$7.10−$0.1900 (−2.61%) on the dayAs of the close; data may be delayed.
ALMS price, last 12 months
Key stats
- Previous close
- $7.29
- Open
- $7.33
- Day range
- $7.04 – $7.38
- 52-week range
- $3.76 – $31.35
- Volume
- 1.7M
- Avg volume (20 days)
- 5.1M
- Market cap
- $919.0M
Performance
1W−8.6%
1M−69.9%
3M−73.1%
6M−73.0%
YTD−27.3%
1Y+71.5%
vs S&P 500, 1Y+54.7 pts
Technicals and fundamentals
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $919.0M